

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
26 July 2017**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES ACT OF 1933 AND  
THE SECURITIES EXCHANGE ACT OF 1934**

**Sage Therapeutics, Inc.  
File Nos. 1-36544 and 333-196849**

**CF# 35197**

-----

Sage Therapeutics, Inc. submitted an application under Rules 406 and 24b-2 requesting an extension of previous grants of confidential treatment for information it excluded from the Exhibits to Form 10-Q filed on November 6, 2015 and Form S-1/A filed on July 8, 2014.

Based on representations by Sage Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

<b>Exhibit</b>	<b>to Form</b>	<b>Filed on</b>	<b>Confidential Treatment Granted</b>
10.2	10-Q	November 6, 2015	through May 30, 2020
10.3	S-1/A	July 8, 2014	through May 30, 2020
10.4	S-1/A	July 8, 2014	through May 30, 2020
10.5	S-1/A	July 8, 2014	through May 30, 2020
10.18	S-1/A	July 8, 2014	through May 30, 2020

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields  
Secretary